Cyxone makes further strides with Rabeximod phase IIb trial by signing CRO EGeen Inc.
Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has signed an agreement with EGeen Inc., a clinical research organization (CRO), for conducting its upcoming clinical phase IIb trial with Rabeximod in rheumatoid arthritis (RA) in select Eastern European countries. Cyxone is now, together with several partners, finalizing the necessary applications for permission to run its phase IIb multicenter study in both Western and Eastern Europe. The first application has been submitted and the remaining, up to eight, applications are expected to be submitted